Donald G Musson

Title: The Innovations of Donald G Musson

Introduction

Donald G Musson is a notable inventor based in Upland, CA (US). He has made significant contributions to the field of ophthalmic therapeutics, holding a total of 2 patents. His work focuses on innovative solutions for reducing intraocular pressure and stabilizing pharmaceutical preparations.

Latest Patents

One of Musson's latest patents is for Ketaneserinol as an agent to reduce intraocular pressure. This invention relates to the use of ketanserinol as an ophthalmic therapeutic agent aimed at treating glaucoma. The method involves the systemic administration of ketanserinol, its salts, esters, or prodrugs, particularly through topical application to the eye. Another significant patent is for a stabilizing preparation for thymoxamine. In this work, experiments were conducted to test the stability of thymoxamine in aqueous solutions at room temperature and above. The findings revealed that dimethyl-beta-cyclodextrin slows the hydrolysis degradation of thymoxamine, while other beta-cyclodextrin analogs either accelerate degradation or have no effect. Cytological experiments demonstrated that formulations containing thymoxamine and up to 5% by weight dimethyl-beta-cyclodextrin exhibit the same toxicity as those with thymoxamine alone.

Career Highlights

Musson is currently associated with Iolab Corporation, where he continues to innovate in the field of ophthalmology. His work has contributed to advancements in therapeutic agents that address critical health issues related to eye pressure.

Collaborations

Some of his notable coworkers include Orest Olejnik and Ramon L Espino, who have collaborated with him on various projects.

Conclusion

Donald G Musson's contributions to ophthalmic therapeutics through his patents reflect his dedication to improving patient care. His innovative approaches continue to influence the field and provide valuable solutions for treating glaucoma and stabilizing pharmaceutical compounds.